Organization
Netherlands Comprehensive Cancer Organisation (IKNL)
6 abstracts
Abstract
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).Org: The Netherlands Cancer Institute, Erasmus MC Cancer Institute, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus School of Health Policy & Management, Spaarne Gasthuis,
Abstract
Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, University Medical Center Utrecht, Utrecht University, Department of Clinical Data Science, Netherlands Comprehensive Cancer Organisation (IKNL),
Abstract
Nationwide implementation of best practices in pancreatic cancer care (PACAP-1): Stepped-wedge cluster randomized trial.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, University of Amsterdam, Netherlands Comprehensive Cancer Organisation (IKNL), Department of Surgery, Brigham and Women's Hospital, Boston, MA, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan,
Abstract
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).Org: University Medical Center Utrecht, Utrecht University, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus Medical Center, Amsterdam University Medical Centers,
Abstract
The number of lymph nodes examined as a poor prognosis factor in stage II and stage III colon cancer patients undergoing curative surgery.Org: Yonsei University College of Medicine, Netherlands Comprehensive Cancer Organisation (IKNL), Yonsei Cancer Center, Yonsei University Health System, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Patient-reported symptom monitoring linked to an alert algorithm: Effects on progression-free and overall survival in the SYMPRO-Lung trial.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Netherlands Comprehensive Cancer Organisation (IKNL), The Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences,